Changcheng Zhu
Thoracic pathology, Head & Neck Pathology, Gynecological Pathology and Lung Transplant Pathology<br /><quillbot-extension-portal></quillbot-extension-portal>
Lung cancer<br />
Thoracic pathology, Head & Neck Pathology, Gynecological Pathology and Lung Transplant Pathology<br /><quillbot-extension-portal></quillbot-extension-portal>
Lung cancer<br />
Dr. Weithorn focuses on using minimally invasive techniques, including robotic surgery, to treat a wide range of surgical diseases, including gallstones (gallbladder removal), hiatal hernia repair, anti-reflux surgery, diverticulitis, colon cancer, ventral and inguinal hernias including complex hernias, recurrent ventral and inguinal hernias, and neurectomy procedures for chronic inguinal pain after inguinal hernia repair.
Dr. Weithorn is interested in outcomes-based research using minimally invasive surgical techniques to reduce morbidity and speed recovery for a wide range of general surgical conditions, especially acute and/or emergent surgical conditions. H
<p>David Weithorn, MD, is a general surgeon and Assistant Professor, Surgery at Montefiore Einstein. A fellowship-trained minimally invasive general surgeon, Dr. Weithorn focuses on using minimally invasive techniques, including robotic surgery, to treat a wide range of surgical diseases, including gallstones (gallbladder removal), hiatal hernia repair, anti-reflux surgery, diverticulitis, colon cancer, ventral and inguinal hernias including complex hernias, recurrent ventral and inguinal hernias, and neurectomy procedures for chronic inguinal pain after inguinal hernia repair.</p><p>After receiving his Bachelor of Science from University of Florida in 2011, Dr. Weithorn attended the Herbert Wertheim College of Medicine, earning his Doctor of Medicine in 2015. He completed his residency in general surgery at Montefiore Medical Center in 2020, then pursued fellowship in robotic/minimally invasive surgery at Hackensack University Medical Center, training with pioneers in robotic surgery.</p><p>Dr. Weithorn is interested in outcomes-based research using minimally invasive surgical techniques to reduce morbidity and speed recovery for a wide range of general surgical conditions, especially acute and/or emergent surgical conditions. He has shared his work through peer-reviewed journal articles and national presentations.</p><p>Dr. Weithorn is board certified by the American Board of Surgery and is a member of the American College of Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons.</p>
<p>Dr. Tokayer received his B.A. in from Yeshiva College and his M.D. from Albert Einstein College of Medicine of Yeshiva University. He completed an internship and residency at the Bronx Municipal Hospital Center and GI and Hepatology fellowship at Johns Hopkins Medical Center. He received an MHS degree in Clinical Epidemiology from Johns Hopkins School of Public Health. Dr. Tokayer then joined the Montefiore GI Faculty in 1992. He has been involved in the spectrum of clinical patient care, endoscopic interventions and teaching in the GI fellowship program. His areas of interest include clinical practice, patient care and education, endoscopic procedures and interventions, functional GI and motility disorders. He is Director of the GI Motility Lab where studies such as Esophageal Manometry, Esophageal Acid Monitoring and Impedance Testing, Ano-rectal Manometry and Defecatory Testing, Hydrogen Breath Testing for Bacterial overgrowth and Carbohydrate Maldigestion , and studies of gastric and intestinal transit. He works closely with colleagues of the Department of Radiology and Nuclear Medicine as well as the Department of Surgery in diagnosing and treating GI motility disorders.</p>
<p>In-patient internal medicine with a special interest in hematology. Anemia, thrombocytopenia and coagulopathy in hospitalised patients.</p>
Colon cancer screening<quillbot-extension-portal></quillbot-extension-portal>
Colon cancer screening<quillbot-extension-portal></quillbot-extension-portal>
<p>Howard I. Sherman, MD, is an attending physician and Adjunct Associate Clinical Professor, Gastroenterology at Montefiore Einstein. His clinical focus centers on colon cancer screening.</p><p>After earning his Doctor of Medicine at Einstein in 1973, Dr. Sherman began his postdoctoral training at Emory University. There, he completed his medical internship in 1974, his internal medicine residency in 1976 and a digestive diseases fellowship in 1978.</p><p>Building on his clinical focus, Dr. Sherman’s research is focused on colon cancer screening.</p><p>Dr. Sherman is board certified in Gastroenterology and is a Diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. He is a member of several professional organizations, including the American Gastroenterology Association, the American College of Gastroenterology, the American Society for Gastrointestinal Endoscopy and the American Association for the Study of Liver Disease.</p>
<p>Jonathan M. Schwartz is a board Certified Transplant Hepatologist. He is a graduate of Tel Aviv University, Sackler School of Medicine. He was an Internal Medicine Resident at Albert Einstein College of Medicine and a Fellow in Gastroenterology/Transplant Hepatology at the University of Washington in Seattle. He returned to New York in 2011 from Portland, Oregon where he served as an Associate Professor of Medicine at Oregon Health and Sciences University.</p>
<p>Dr. Schwartz has an interest in treating patients with acute and chronic liver diseases including those patients with advanced liver diseases who require liver transplantation.</p>
<p>He has a special interest in the multidisciplinary care of patients with liver tumors.</p>
<p><strong><br /></strong></p>
<ul>
<li>Estes JD, Stolpman D, Olyaei A, Ham JM, <strong>Schwartz JM</strong>, Orloff SL. High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Fulminant Hepatic Failure Patients. Arch Surg. 2003;138(8):852-8.</li>
<li><strong>Schwartz JM</strong>, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman D, Kowdley KV. Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure. J Clin Gastroenterol 2004;38(7):590-594.</li>
<li>Lim LL, Scarborough J, Thorne J, Graham E, Kempen J, Mackensen F, Nguyen Q D, Prabriputaloong T, Read R, Suhler EB, <strong>Schwartz JM</strong>, Smith JR. Uveitis in Patients with Autoimmune Hepatitis. Am J Ophthalmol. 2009;147(2):332-338.</li>
<li>O’Glasser AY, Scott DA, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, and <strong>Schwartz JM.</strong>Hepatic and Cardiac Iron Overload Among Patients with End-Stage Liver Disease Referred for Liver Transplantation. Clinical Transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51.</li>
<li>Kanwal F, Befeler A, Chari R, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, <strong>Schwartz J</strong>, Van Thiel D, Hassanein TI, Li J, Zeringue A, DiBisceglie A. Rate of Potentially Curative Treatment in Patients with Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2012 Aug;36(3):257-65.</li>
<li>Bichoupan K1, <strong>Schwartz JM,</strong> Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H,Dieterich DT, Branch AD, Reinus JF. Effect of Fibrosis on Adverse Events in Patients with Hepatitis C Treated with Telaprevir. Aliment Pharmacol Ther. 2014;39(2):209-16.</li>
<li><strong>Schwartz J</strong> and Carithers RL. Epidemiology and Etiologic Associations of Primary Hepatocellular Carcinoma. In Rose BD, editor. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li><strong>Schwartz JM </strong>and Carithers RL, Jr. Clinical features, diagnosis, and screening for primary hepatocellular carcinoma. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Curley SA, Stewart KE, <strong>Schwartz JM</strong>, Carthers RL, Jr. Nonsurgical therapies for localized hepatocellular carcinoma. Up to date, Inc. Wellesley, MA, Updated 2014.<strong> </strong></li>
<li><strong>Schwartz JM</strong>. Approach to the patient with a focal liver lesion. Up to date Inc Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Hartwell L and <strong>Schwartz JM. </strong>AsymptomaticLiver Chemistry Abnormalities. Journal of Clinical Outcomes Management. 2009; 16 (11): 525-34.</li>
<li>Urquhart J<strong>, Schwartz, JM.</strong> Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011.</li>
<li><strong>Schwartz, JM </strong>and Reinus JF. Prevalence and Natural History of Alcoholic Liver Disease. Clinics in Liver Disease. 2012; 16 (4): 659-66.</li>
</ul>
<p> </p>